Rare mutations at EGFR L747 position: molecular characteristics and superior response to afatinib in NSCLC patients
Yunchao Huang(Zhejiang Chinese Medical University), Wen‐Feng Fang(Sun Yat-sen University)
Cited by 0
Related Papers
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
|The Lancet Respiratory Medicine|2021|183
A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial
|Nature Medicine|2025|76
Household air pollution and epigenetic aging in Xuanwei, China
|Environment International|2023|26